HTA-Information Service Rapid Reviews

Since 2023, the Austrian Institute for Health Technology Assessment (AIHTA) is supporting the decisions of Austrian social insurance funds with short evidence syntheses as well as those of hospital providers with factsheets on new, expensive medicines. The aim is to support these decisions on medical services with evidence. The best available evidence from current reviews and clinical trials is summarised.

HTA-Information Service Rapid Review No. 001 
iv Immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss

HTA-Information Service Rapid Review No. 002 
Extracorporeal shock wave therapy for orthopaedic indications